“‘Someday’ is Now!”: Anpac Bio & Med Partners Celebrate ‘National Cancer Prevention Month’ Surpassing 60,000 ‘Liquid Biopsy’ Cases
Anpac Bio-Medical Science Company (Anpac Bio), and its internationally-acclaimed medical research partners and hospitals, are celebrating “World Cancer Day” (#WorldCancerDay) and “National Cancer Prevention Month” (#NationalCancerPreventionMonth) by surpassing a new, global milestone: processing over 60,000, independently-corroborated cases of Anpac Bio’s proprietary, “Cancer Differentiation Analysis” (CDA) liquid biopsy tests worldwide.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180204005101/en/
Anpac Bio-Medical Science Company CEO Dr. Chris Yu inspects one of the company's proprietary "Cancer Differentiation Analysis" (CDA) liquid biopsy technology devices before screening simple, standard blood tests signals of early disease. Anpac Bio's CDA technology consistently detects 26+ cancers, with a 75%-90% sensitivity/specificity rates, usually identifying the disease at its earliest stages. And it does so without any harmful side effects in patients; generating far fewer "false positives"; at a cost substantially lower than traditional testing; and generating results within minutes of sample submission. Fully-commercialized with 200 patents filed worldwide, Anpac Bio and its respected medical research partners are celebrating #NationalCancerPreventionMonth by surpassing a new global milestone: processing 60,000+ independently-corroborated CDA tests for early cancer screening and detection; as well as monitoring cancer treatment, effectiveness, and recurrence. (Photo: Business Wire)
World-renowned, Second Military Medical University and its affiliated Changhai Hospital (CH) in Shanghai, China, have conducted 4,000+ CDA liquid biopsy tests since 2014. Submitting Lung, Esophageal Cancer, and cancer-free control group blood samples, “blinded” to Anpac Bio, CH concluded CDA is a remarkably accurate, non-invasive test, supporting both early diagnosis, and monitoring treatment effectiveness, prognosis, and recurrence.
“Our preliminarily results indicate that CDA technology has better sensitivity and specificity for early diagnosis, as well as potentially a good tool for treatment assessment for Lung Cancer and Esophageal Cancer than traditional tumor markers,” reports Dr. Jun-Jie Wu, Deputy Chief Physician, CH Department of Oncology. “It (CDA) can also play a good role in complementing chest CT (Computerized Axial Tomography) screening for pulmonary nodules. The existing data suggests that CDA technology is a promising technology in the field of diagnosis and treatment assessment of Lung Cancer and cancer of the Esophagus.”
Described as “game changing” and receiving the “Breakthrough Innovation Award” at the World Nobel Prize Laureate Summit; and named “Most Promising Cancer Screening Company” at the 2017 Global Precision Medicine Industry Awards , Anpac Bio’s CDA technology effectively reinvents early cancer screening and detection.
By analyzing simple, standard, blood tests, and applying Anpac Bio’s proprietary, multi-level, multi-parameter, diagnostic algorithms, Anpac Bio’s CDA technology identifies cancer with measurably-greater accuracy than most current, conventional screening methods. And it does so without any harmful side effects in patients; generating far fewer “false positives”; at a cost substantially lower than traditional testing; and generating results within minutes of sample submission.
Comprehensive research validity data from 60,000+ cases processed to date demonstrate CDA diagnostics consistently detects 26+ cancers -- with a sensitivity and specificity rate range of 75%-90% -- usually identifying the disease at its earliest stages.
The Oncology Department of Shanghai Changzheng Hospital (SCH) corroborates these results. Since 2016, SCH has conducted two comprehensive clinical research studies of Anpac Bio’s CDA liquid biopsy technology. Submitting over 500 healthy “control” group; “high-risk” group (those genetically or environmentally pre-disposed to developing cancer); and independently-diagnosed and “confirmed cancer” group blood samples; for CDA analysis.
According to study director and SCH Deputy Professor Dr. Yuan Sheng Zang: “Initial results indicated that CDA technology has better sensitivity and specificity for early-stage cancer screening than that of traditional tumor markers. The evaluation on the significance of CDA technology in prognosis is ongoing. The existing research data suggest that CDA technology has a good prospect in the field of cancer diagnosis and prognosis.”
Pioneering liquid biopsy research (launched in 2008), Anpac Bio is already, fully-commercialized and generating revenue from Fortune 500 corporate, insurance, medical, research, and individual (“over the counter”) testing; while most competing “liquid biopsy” research remains in the laboratory and unavailable to the general public (for perhaps years).
Additionally, competing tests generally measure only single/few sample indicators (such as gene mutations that may indicate a patient’s increased risk or probability of potentially developing cancer at some point). Anpac Bio’s CDA is a “functional biology” test – providing medical professionals important information regarding actual disease signals present in the patient’s body at the moment of blood draw.
CDA’s independently-confirmed, very early stage cancer and pre-cancerous disease detection’s efficiency and accuracy is due to the technology’s multi-level and multi-parameter, patented design. With over 200 CDA-related patent applications worldwide (65+ currently issued), CDA’s integrated system measures numerous protein, molecular, cellular, and other factors, to identify disease signals. By enhancing signal detection and processing, while reducing “noise”, the collected data is subsequently analyzed using Anpac Bio’s proprietary algorithms.
The resulting data is then assigned an overall value, called “CDA Value”, indicating cancer incidence risk level (the higher the CDA Value, the higher the cancer risk). CDA’s accuracy and advantages have been verified in previous studies, and presented before respected scientific organizations, such as the American Society of Clinical Oncology (ASCO), the Breast Cancer Symposium, and the World Nobel Prize Laureate Summit.
“Every day, our company hears of other, potential ‘liquid biopsy’ tests that report ‘someday’ may be used to catch cancer,” states Dr. Chris Yu, Anpac Bio Chief Executive Officer. “Our CDA technology has been extensively tested, verified, and used daily by dozens of Asia’s most well-respected and renowned medical institutions. We are also generating equally accurate and positive results in the United States. We’re very proud that our CDA devices have advanced well-beyond the laboratory and are processing real tests for real people – saving lives every day. On this ‘National Cancer Prevention Month’, Anpac Bio and our medical partners want the world to know: ‘Someday’ is now!”
For more information about Anpac Bio please check: www.AnpacBio.com.
Anpac Bio-Medical Science Company
Drisha Leggitt, 916-206-2553
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Schlumberger Announces Second-Quarter 2018 Results20.7.2018 14:00 | Tiedote
Schlumberger Limited (NYSE: SLB) today reported results for the second quarter of 2018. (Stated in millions, except per share amounts) Three Months Ended Change Jun. 30, 2018 Mar. 31, 2018 Jun. 30, 2017 Sequential Year-on-year Revenue $8,303 $7,829 $7,462 6% 11% Pretax operating income $1,094 $974 $950 12% 15% Pretax operating margin 13.2% 12.4% 12.7% 75 bps 45 bps Net income - GAAP basis $430 $525 $(74) -18% n/m Net income, excluding charges & credits* $594 $525 $488 13% 22% Diluted EPS - GAAP basis $0.31 $0.38 $(0.05) -18% n/m Diluted EPS, excluding charges & credits* $0.43 $0.38 $0.35 13% 23% *These are non-GAAP financial measures. See section below entitled "Charges & Credits" for details. n/m = not meaningful Schlumberger Chairman and CEO Paal Kibsgaard commented, “The second quarter was both busy and exciting for Schlumberger as we completed a number of major milestones in preparation for the broad-based global activity upturn that is now emerging. We delivered solid top-line gro
H.I.G. Capital Announces the Sale of KidsFoundation19.7.2018 22:50 | Tiedote
H.I.G. Capital (“H.I.G.”), a leading global private equity investment firm with more than €21 billion of equity capital under management, announced today that one of its affiliates has entered a definitive agreement to sell the KidsFoundation Group (“KidsFoundation”), the Dutch market leader in childcare services, to Onex Corporation (“Onex”)(TSX:ONEX). Terms were not disclosed. Headquartered in Almere, the Netherlands, KidsFoundation provides high-quality childcare to nearly 30,000 children between the ages of six weeks and 12 years. H.I.G. created KidsFoundation in 2014 through the acquisition of assets from the estate of Estro Group. During H.I.G.’s ownership, the company has developed strongly with significant capital invested by H.I.G. to create a high-quality childcare offering. H.I.G. worked with KidsFoundation management to optimise the footprint of the company by exiting loss-making locations, introduce new IT systems to drive operational improvement and develop an internal M&
SIG Combibloc Group Holdings S.à r.l.: 2018 Second Quarter Results19.7.2018 19:01 | Tiedote
We are pleased to announce our quarterly conference call to discuss the results of SIG Combibloc Group Holdings S.à r.l. for the second quarter ended June 30, 2018. Date: Monday, July 23, 2018 Time: 15.00 CEST / 14.00 BST / 9.00 EDT The call information will be distributed on our secure site. If you would like access to our call, please contact email@example.com . Regards, SIG Combibloc Group Holdings S.à r.l. View source version on businesswire.com: https://www.businesswire.com/news/home/20180719005634/en/ Contact information SIG Combibloc Group Holdings S.à r.l. Jennifer Gough firstname.lastname@example.org
NEORIS Announces Creation of Innovation Labs Worldwide to Create a Smarter Future19.7.2018 18:32 | Tiedote
NEORIS, a global digital consulting services company, announced today it is consolidating the most innovative solutions it has developed in different geographies and allocating unprecedented resources to deploy a network of Innovation Labs worldwide. The main objective is to lay the foundation for the continuous development of disruptive solutions for its four core industries: Manufacturing, Financial Services, Healthcare and Telecommunications. Due to its disruptive nature, NEORIS decided that its first Innovation Lab should be housed in the Monterrey Digital Hub, which today is the first-of-its-kind as it is a space where entrepreneurs, companies, universities and investors converge to foster an ecosystem for Digital Transformation. The lab inaugurated in Monterrey, Mexico is the first of a series of Innovation Labs that will open in the different countries that NEORIS operates, and is a space where customers can experience emerging technologies through real-life scenarios. One such
CORRECTING and REPLACING Albar Capital Deploys FlexNOW19.7.2018 18:29 | Tiedote
Subhead of release should read: Out-of-the-Box Multi-Asset Execution Management System (instead of Easy-to-Install Multi-Asset Execution Management System). The corrected release reads: ALBAR CAPITAL DEPLOYS FLEXNOW Out-of-the-Box Multi-Asset Execution Management System FlexTrade (@FlexTrade) today announced that Albar Capital Ltd., a new hedge fund led by Javier Velazquez (formerly of Millennium Capital Partners LLP), is now trading equities and futures using FlexNOW, FlexTrade’s new execution management system. “The FlexNOW team was instrumental in solving several of our problems,” said Jason Ruder, Trader at Albar Capital. “Not only are they helping us with our compliance requirements, they are also responsive to requests that improve my workflow.” According to Rhyd Lewis, FlexNOW Product Manager, FlexNOW’s quick onboarding and easy installation process was critical for Albar Capital’s launch on 2 July. “We had no problem integrating FlexNOW with Albar’s portfolio and risk managemen
Full Core of Westinghouse Fuel Achieved at South-Ukraine Nuclear Power Plant Unit 319.7.2018 16:25 | Tiedote
Westinghouse Electric Company announced today that Ukraine’s State Enterprise National Nuclear Energy Generation Company (SE NNEGC) Energoatom’s South-Ukraine NPP Unit 3 near Yuzhnoukrainsk in Mykolaiv province was loaded with a full core of Westinghouse VVER-1000 fuel. This is the first unit in Ukraine to operate with Westinghouse VVER-1000 fuel assemblies as the sole fuel source. “Westinghouse began supplying fuel to Ukraine in 2005, when the first lead test assemblies were delivered to South-Ukraine Unit 3,” said Aziz Dag, vice president and managing director, Northern Europe. “We are proud to continue supporting Ukraine with their energy diversification by supplying a full core of Westinghouse VVER-1000 fuel to our customer, Energoatom.” Westinghouse currently supplies fuel to six of Ukraine’s 15 nuclear power reactors. Beginning in 2021, the number of reactors with Westinghouse fuel will increase to seven. “Westinghouse has made significant investments over the last several years
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme